<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Pharmaceuticals on Korea Invest Insights</title><link>https://koreainvestinsights.com/tags/pharmaceuticals/</link><description>Recent content in Pharmaceuticals on Korea Invest Insights</description><generator>Hugo -- gohugo.io</generator><language>en</language><copyright>koreainvestinsights.com · @korea_invest_insights</copyright><lastBuildDate>Fri, 06 Nov 2026 23:40:02 +0900</lastBuildDate><atom:link href="https://koreainvestinsights.com/tags/pharmaceuticals/feed.xml" rel="self" type="application/rss+xml"/><item><title>Korea Quality Re-Rating Watch 2026-11-06: HMM, Hanmi Pharm &amp; Dongkook Lead</title><link>https://koreainvestinsights.com/post/kr-daily-wrap-2026-11-06/</link><pubDate>Fri, 06 Nov 2026 16:30:00 +0900</pubDate><guid>https://koreainvestinsights.com/post/kr-daily-wrap-2026-11-06/</guid><description>&lt;h2 id="macro-dashboard"&gt;Macro Dashboard
&lt;/h2&gt;&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th&gt;Indicator&lt;/th&gt;
 &lt;th&gt;Level&lt;/th&gt;
 &lt;th&gt;5-Day Change&lt;/th&gt;
 &lt;th&gt;Signal&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td&gt;KOSPI&lt;/td&gt;
 &lt;td&gt;5,060&lt;/td&gt;
 &lt;td&gt;−13.6%&lt;/td&gt;
 &lt;td&gt;Bear&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;KOSDAQ&lt;/td&gt;
 &lt;td&gt;644&lt;/td&gt;
 &lt;td&gt;−12.3%&lt;/td&gt;
 &lt;td&gt;Bear&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;USD/KRW&lt;/td&gt;
 &lt;td&gt;1,356&lt;/td&gt;
 &lt;td&gt;+2.3%&lt;/td&gt;
 &lt;td&gt;KRW weak&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;VIX&lt;/td&gt;
 &lt;td&gt;26.8&lt;/td&gt;
 &lt;td&gt;+26.6%&lt;/td&gt;
 &lt;td&gt;Caution&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Brent&lt;/td&gt;
 &lt;td&gt;$98.4&lt;/td&gt;
 &lt;td&gt;−6.1%&lt;/td&gt;
 &lt;td&gt;Falling&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;US 10Y&lt;/td&gt;
 &lt;td&gt;4.84%&lt;/td&gt;
 &lt;td&gt;−0.09pp&lt;/td&gt;
 &lt;td&gt;Stable&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;p&gt;&lt;strong&gt;Korea regime: Bear. US regime: Neutral&lt;/strong&gt; — the US just downgraded from Bull this run. Only 14.5% of Korean stocks trade above their 50-day moving average; 12.8% above the 200-day. KOSPI sits at 5,060 against a 200DMA of 6,511. KRX program selling hit −₩1.61 trillion on the session, basis −0.28.&lt;/p&gt;
&lt;hr&gt;
&lt;h2 id="market-wrap"&gt;Market Wrap
&lt;/h2&gt;&lt;p&gt;&lt;em&gt;Source: KR Market Snapshot, 2026-11-06. No same-day close briefing was available; a stale prior briefing was intentionally blocked.&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;Today&amp;rsquo;s session was a broad, largely indiscriminate selloff. Of 2,595 stocks tracked, 2,035 declined and only 335 advanced — an advance-decline ratio of roughly 1:6. The average stock fell 2.34%. Program selling (−₩1.61 trillion net, nearly all non-arbitrage) confirmed systematic de-risking rather than targeted rotation. ETF net creation was a modest +₩181 billion — passive inflows providing a marginal cushion against the tide.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Batteries and semiconductors led the decline.&lt;/strong&gt; Samsung SDI (006400.KS, −8.06%), LG Chem (051910.KS, −5.69%), EcoPro (086520.KS, −6.89%), and L&amp;amp;F (066970.KQ, −12.60%) all fell sharply, with institutions actively selling SDI and L&amp;amp;F. On the semiconductor side, TES (095610.KS, −11.59%), Dooson Tesna (131970.KS, −10.85%), FADU (440110.KQ, −10.27%), and TCK (064760.KQ, −11.41%) were battered. Korea Finance Holdings (071050.KS, −17.34%) stood out as the worst single-name move, with heavy institutional selling.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Internet and IT services were the clearest defensive pocket.&lt;/strong&gt; NAVER (035420.KS, +2.87%) was the only large-cap that attracted both foreign and institutional buying simultaneously. Samsung SDS (018260.KS, +6.34%) also drew institutional flows. Samsung Biologics (207940.KS, −0.26%) was nearly flat — the healthiest of the defensives among large caps.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Foreign flow diverged from price.&lt;/strong&gt; Foreigners sold financials outright: KB Financial (105560.KS, −3.82%), Woori Financial (316140.KS, −1.72%), and Shinhan (055550.KS, −2.25%) all saw foreign outflows. Samsung C&amp;amp;T (028260.KS, −5.85%) and Samsung SDI were also on the foreign sell list. On the other side, foreigners bought POSCO Holdings (005490.KS, −3.11%) and TES despite price declines — a potential signal for recovery scenarios.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Institutions bought financials that foreigners sold.&lt;/strong&gt; KB Financial, Woori, Shinhan, and Hyundai Motor (005380.KS) all appeared on institutional buy lists. The setup — foreign selling, domestic institutional absorbing — may reflect a rotation toward domestic yield plays as Korean 10-year bonds fell to 3.887%, a five-week low. Korean AA− corporate spreads over 3-year KTBs tightened to 0.69pp, one of the more stable readings in the current drawdown.&lt;/p&gt;
&lt;hr&gt;
&lt;h2 id="todays-quality-re-rating-candidates"&gt;Today&amp;rsquo;s Quality Re-Rating Candidates
&lt;/h2&gt;&lt;p&gt;&lt;em&gt;Source: KR Meta Screener, 2026-11-06. The PEAD-only screener intersection shows no 2+ overlaps today on that dimension; multi-signal analysis draws on the full meta screener combining 8 screener families across 104 tickers.&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;Today&amp;rsquo;s meta screener calibrates weights on 95 days of live forward returns. The dominant signal is &lt;strong&gt;consensus revision (2.18× weight, +1.76pp vs. pool average over 97 sample days)&lt;/strong&gt;. RS80 leadership (1.31×) and quiet accumulation (1.00×) follow. The financial-quality factor cluster — Quality Compounder, Smart Money Quality, Cycle Rerating, Smart Money Earnings — carries 0.60× per family, meaningful when stacked but not dominant alone.&lt;/p&gt;
&lt;h3 id="top-candidates--2026-11-06"&gt;Top Candidates — 2026-11-06
&lt;/h3&gt;&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th&gt;Rank&lt;/th&gt;
 &lt;th&gt;Ticker&lt;/th&gt;
 &lt;th&gt;Name&lt;/th&gt;
 &lt;th&gt;Meta Score&lt;/th&gt;
 &lt;th&gt;Screener Families&lt;/th&gt;
 &lt;th&gt;Evidence Pts&lt;/th&gt;
 &lt;th&gt;Key Metrics&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td&gt;1&lt;/td&gt;
 &lt;td&gt;011200.KS&lt;/td&gt;
 &lt;td&gt;HMM&lt;/td&gt;
 &lt;td&gt;34.2&lt;/td&gt;
 &lt;td&gt;Consensus Up, Quiet Accum., RS80&lt;/td&gt;
 &lt;td&gt;4&lt;/td&gt;
 &lt;td&gt;Consensus z +0.52; retail −₩21.96B; RS80 pivot gap +10.5%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;2&lt;/td&gt;
 &lt;td&gt;128940.KS&lt;/td&gt;
 &lt;td&gt;Hanmi Pharm&lt;/td&gt;
 &lt;td&gt;54.7&lt;/td&gt;
 &lt;td&gt;Consensus Up, Cycle, SM Quality, SM Earnings&lt;/td&gt;
 &lt;td&gt;5&lt;/td&gt;
 &lt;td&gt;Margin +2.2pp; F+QI net +₩73.3B 5-day; DART catalyst&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;3&lt;/td&gt;
 &lt;td&gt;086450.KS&lt;/td&gt;
 &lt;td&gt;Dongkook Pharma&lt;/td&gt;
 &lt;td&gt;68.1&lt;/td&gt;
 &lt;td&gt;Quality, Cycle, PEAD, Quiet Accum.&lt;/td&gt;
 &lt;td&gt;5&lt;/td&gt;
 &lt;td&gt;ROE 9.9%; OP YoY +20.1%; margin +0.5pp&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;4&lt;/td&gt;
 &lt;td&gt;089590.KS&lt;/td&gt;
 &lt;td&gt;Jeju Air&lt;/td&gt;
 &lt;td&gt;23.3&lt;/td&gt;
 &lt;td&gt;Consensus Up&lt;/td&gt;
 &lt;td&gt;3&lt;/td&gt;
 &lt;td&gt;Consensus z +5.78; IR event catalyst; retail −₩10.65B&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;5&lt;/td&gt;
 &lt;td&gt;071970.KS&lt;/td&gt;
 &lt;td&gt;HD Hyundai Marine Engine&lt;/td&gt;
 &lt;td&gt;20.5&lt;/td&gt;
 &lt;td&gt;Consensus Up&lt;/td&gt;
 &lt;td&gt;3&lt;/td&gt;
 &lt;td&gt;Consensus z +0.51; Q3 prelim + supply contract filed&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;6&lt;/td&gt;
 &lt;td&gt;079160.KS&lt;/td&gt;
 &lt;td&gt;CJ CGV&lt;/td&gt;
 &lt;td&gt;19.1&lt;/td&gt;
 &lt;td&gt;Consensus Up&lt;/td&gt;
 &lt;td&gt;2&lt;/td&gt;
 &lt;td&gt;Consensus z +0.83; Q3 prelim filed today&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;7&lt;/td&gt;
 &lt;td&gt;383800.KS&lt;/td&gt;
 &lt;td&gt;LX Holdings&lt;/td&gt;
 &lt;td&gt;17.0&lt;/td&gt;
 &lt;td&gt;Consensus Up&lt;/td&gt;
 &lt;td&gt;2&lt;/td&gt;
 &lt;td&gt;Consensus z +3.88; Q3 prelim filed Nov 4&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;h3 id="top-3-in-detail"&gt;Top 3 in Detail
&lt;/h3&gt;&lt;p&gt;&lt;strong&gt;#1 — HMM (011200.KS): Three Independent Signals, No DART Risk Flags&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;HMM is Korea&amp;rsquo;s largest container shipping line. It ranks first because it combines three independently weighted signal families: rising analyst consensus (z +0.52), quiet accumulation by foreigners and quality institutions while retail sold −₩21.96 billion, and RS80 leadership that cleared the late-stage filter (20-day flow/volume momentum +21.6%, box risk −14.7%). No filings appeared in the DART lookback window — the absence of risk disclosures is a clean read in the current environment. The RS80 weight (1.31×) stacked on consensus (2.18×) explains the top meta rank despite fewer quality-factor signals than the names below it. What to check next: spot freight rate trends and Q3 earnings timing.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;#2 — Hanmi Pharm (128940.KS): DART Catalyst + Four Screeners + Smart Money vs. Retail Divergence&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Hanmi Pharmaceutical is one of Korea&amp;rsquo;s leading biopharmaceutical companies, known for GLP-1, oncology, and rare disease pipelines. It hits four screener families: Cycle Rerating (operating margin expanded +2.2pp), Smart Money Quality (foreigners and quality institutions absorbed a net +₩73.3 billion over five days while retail sold −₩58.83 billion), Smart Money Earnings, and consensus revision. The DART overlay adds confirmed catalysts: a Fabry disease drug (LAGLA) licensing deal filed Oct 30, plus two IR events in late October and early November. The divergence between retail outflows and institutional/foreign inflows is the sharpest flow split in today&amp;rsquo;s candidate pool. What to check next: LAGLA deal geography and upfront payment structure; whether the IR calendar signals Q3 results disclosure.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;#3 — Dongkook Pharma (086450.KS): Quality Compounder + Cycle + PEAD — Operational Leverage Stacking&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Dongkook Pharmaceutical is a mid-cap consumer health and prescription drug company with a branded OTC portfolio alongside ethical pharmaceuticals. It clears four screener families: Quality Compounder (ROE 9.9%, OP YoY +20.1%), Cycle Rerating (margin +0.5pp), PEAD (OP YoY 20%, revenue +14.1%, 52-week gap remaining 21.2%), and quiet accumulation (retail −₩6.85 billion absorbed by foreigners and quality institutions). The raw meta score of 68.1 is the highest in today&amp;rsquo;s pool. It also appears independently in the PEAD Tier C list. The core story is operational leverage: revenue growth converting into margin expansion and beginning to attract institutional re-pricing. What to check next: OTC vs. prescription revenue mix and whether the OP growth rate is sustainable at the current sales base.&lt;/p&gt;
&lt;hr&gt;
&lt;p&gt;&lt;em&gt;All data sourced from Research OS internal DB as of 2026-11-06. Candidates are screener outputs for research prioritization, not buy or sell recommendations. PEAD sub-index intersection: no 2+ overlaps on that dimension today.&lt;/em&gt;&lt;/p&gt;</description></item></channel></rss>